Stock 1521 FRONTAGE HOLDINGS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Frontage Holdings Corporation

Equities

1521

KYG3679P1019

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:03 2024-05-23 am EDT 		5-day change 1st Jan Change
1.25 HKD -1.57% Intraday chart for Frontage Holdings Corporation -2.34% -46.12%
Apr. 01 Frontage Holdings' Net Profit Plunges 59% in 2023 MT
Mar. 28 Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
FRONTAGE HOLDINGS CORPORATION Stock Frontage Holdings Corporation
-46.12% 329M -
MODERNA, INC. Stock Moderna, Inc.
+64.92% 62.59B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.85% 41.18B
B
LONZA GROUP AG Stock Lonza Group AG
+44.76% 40.29B
A
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.9B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.05% 26.21B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.96% 19.09B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.21% 13.08B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.74% 12.26B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.42% 12.05B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1521 Stock
  4. Ratings Frontage Holdings Corporation